Medical Cannabis
Cannabis engages the endocannabinoid system (ECS) — a regulatory network affecting pain, mood, sleep, appetite, inflammation, and autonomic tone. This page summarizes mechanisms, forms, evidence‑informed uses, risks, and how to personalize therapy.
How It Works — The Endocannabinoid System (ECS)
| Component | Role |
|---|
| CB1 receptors | Abundant in CNS; modulate nociception, mood, memory, motor tone, nausea. |
| CB2 receptors | Predominant in immune/hematopoietic cells; modulate inflammation & cytokine signaling. |
| Endocannabinoids | Anandamide (AEA), 2‑AG — retrograde synaptic signaling; “on‑demand” homeostatic modulators. |
| Enzymes | FAAH, MAGL terminate signals; pharmacologic inhibition ↑ endocannabinoid tone. |
| Phytocannabinoids | THC (psychoactive, analgesic, antiemetic, antispasmodic); CBD (non‑intoxicating, anxiolytic, anti‑inflammatory, antiepileptic). |
| Entourage effect | Terpenes + cannabinoids co‑modulate effects (e.g., myrcene — relaxation; limonene — mood; linalool — calming; beta‑caryophyllene — CB2 agonism). |
Cannabinoids — Quick Links
Potential Indications (Evidence‑Informed)
| Domain | Examples |
|---|
| Chronic pain | Arthritis, fibromyalgia, MS; opioid‑sparing potential. |
| Neurologic | Seizure reduction in epilepsies (e.g., CBD product); spasticity in MS; tremor/rigidity in select cases. |
| Cancer care | Chemotherapy‑induced nausea/vomiting; appetite loss; adjunct analgesia. |
| GI / IBD | Symptom relief in Crohn’s, IBS; anti‑inflammatory potential in ulcerative colitis. |
| Mental health | Anxiety disorders, PTSD‑related symptoms, insomnia (individual variability high). |
| Wasting syndromes | HIV/AIDS, cachexia — appetite stimulation. |
| Consider if | Notes |
|---|
| Conventional therapy suboptimal | Use as adjunct; set measurable goals (pain, sleep, function). |
| Risk–benefit acceptable | Screen for psychosis history, CAD/arrhythmia risk, pregnancy/lactation. |
| Local access & legality | Confirm card/prescription rules; product quality (CoA) available. |
| Care team alignment | Coordinate with clinician; monitor drug interactions and outcomes. |
Forms, Onset & Duration
| Form | Onset | Peak / Duration | Use Cases |
|---|
| Inhalation (smoke/vape) | Minutes | Peak 10–30 min / 2–4 h | Breakthrough pain, nausea; precise titration. |
| Oral edibles/capsules | 30–120 min | Peak 2–4 h / 6–8 h+ | Persistent pain, insomnia; start low due to variable absorption. |
| Tinctures (sublingual) | 15–45 min | Peak ~1–2 h / 4–6 h | Balanced control; adjustable dosing. |
| Topicals | Local | Variable | Focal pain, arthritis; minimal systemic effects. |
Rule of thumb: Start low, go slow, stay low. Track dose, timing, effects, side‑effects.
Terpenes & Chemotypes
| Terpene | Potential Effects |
|---|
| Myrcene | Relaxation, muscle ease; may aid sleep. |
| Limonene | Mood elevation, stress modulation. |
| Linalool | Calming, potential anxiolytic. |
| β‑Caryophyllene | CB2‑active; anti‑inflammatory potential. |
| Pinene | Alertness; may counter memory dulling. |
| Chemotype | Use Notes |
|---|
| THC‑dominant | Strong analgesia/antiemesis; higher impairment/anxiety risk in naive users. |
| Balanced (1:1 THC:CBD) | Often well‑tolerated for mixed pain/sleep/anxiety. |
| CBD‑dominant | Daytime function; seizure/anxiety/inflammation with minimal intoxication. |
Safety, Interactions & Contraindications
| Area | Key Points |
|---|
| Common adverse effects | Dizziness, dry mouth, impaired attention/reaction time; anxiety/paranoia (dose‑related, THC‑linked); GI upset with edibles. |
| Interactions | CNS depressants (additive sedation), anticoagulants/antiplatelets (bleeding risk with some products), CYP3A4/CYP2C9/CYP2C19 substrates (levels may change). |
| Driving & safety | Avoid operating vehicles/machinery when impaired; observe local legal limits. |
| Contraindications | Pregnancy/lactation; active psychosis; unstable cardiac disease; severe hepatic impairment (product‑specific). |
| Dependence risk | Lower than many sedative‑hypnotics/opioids; monitor for cannabis use disorder in susceptible individuals. |
Coordinate with your healthcare professional — especially when you take anticoagulants, antiepileptics, antidepressants, or sedatives. Keep products away from children and pets.
Legal & Access
| Topic | Summary |
|---|
| Medical programs | Rules vary by region; many require a clinician’s certification and state registry card. |
| Product quality | Seek certificates of analysis (CoAs): potency (THC/CBD), terpene profile, contaminant screening (pesticides, heavy metals, residual solvents, microbes). |
| Labeling | Verify batch, date, cannabinoid %/mg, serving guidance; child‑resistant packaging. |
Personalizing Your Plan
| Step | Practical Tips |
|---|
| Define goals | Pick 1–2 metrics (pain score, sleep hours, nausea episodes) to track for 2–4 weeks. |
| Select chemotype | Match goals to THC:CBD ratio and terpene profile; start CBD‑forward or balanced for daytime needs. |
| Choose form | Use rapid forms for flares (inhalation) + longer‑acting for baseline (tincture/edible). |
| Titrate | Increase gradually (every 2–3 nights for sleep; every few days for pain) while logging effects/side‑effects. |
| Review & adjust | Re‑evaluate with your clinician; consider tolerance breaks, formulation changes, or adjuncts. |
Further Reading
Educational content only; not medical advice.
